These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10948697)

  • 1. Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.
    Merlé Y; Mallet A; Schmautz E
    J Pharmacokinet Biopharm; 1999 Oct; 27(5):531-54. PubMed ID: 10948697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
    Merlé Y; Tod M
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):363-88. PubMed ID: 11677932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
    Ribbing J; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reduction in between subject variability is not mandatory for selecting a new covariate.
    Lagishetty CV; Vajjah P; Duffull SB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
    Mandema JW; Verotta D; Sheiner LB
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacodynamic modeling and covariate detection for central neural blockade.
    Schnider TW; Minto CF; Bruckert H; Mandema JW
    Anesthesiology; 1996 Sep; 85(3):502-12. PubMed ID: 8853080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.
    Tatarinova T; Neely M; Bartroff J; van Guilder M; Yamada W; Bayard D; Jelliffe R; Leary R; Chubatiuk A; Schumitzky A
    J Pharmacokinet Pharmacodyn; 2013 Apr; 40(2):189-99. PubMed ID: 23404393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric Methods in Population Pharmacokinetics.
    Goutelle S; Woillard JB; Neely M; Yamada W; Bourguignon L
    J Clin Pharmacol; 2022 Feb; 62(2):142-157. PubMed ID: 33103785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitation of drug evaluation in children by population methods and modelling.
    Tod M; Jullien V; Pons G
    Clin Pharmacokinet; 2008; 47(4):231-43. PubMed ID: 18336053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
    Zhang L; Beal SL; Sheinerz LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.